Jing Zhou1,2,3, Xiaojuan Yu1,2, Tao Su1,2, Suxia Wang2,4, Li Yang1,2. 1. Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China. 2. Renal Pathology Center, Institute of Nephrology, Beijing, China. 3. Renal Division, Department of Medicine, Kailuan General Hospital, Tangshan, China. 4. Laboratory of Electron Microscopy, Pathological Center, Peking University First Hospital, Beijing, China.
Abstract
OBJECTS: This study aimed to analyze the clinicopathological features of acute kidney disease (AKD) with renal oxalosis. METHODS: Data for biopsy-proven AKD with oxalosis diagnosed from Jan 2011 to Oct 2018 was collected. The underlying diseases, dietary habits, clinical and pathological characteristics of newly emerging kidney disease were analyzed. The long-term renal prognosis was observed. RESULTS: A total of 23 patients were included, comprised of 18 men and 5 women with a mean age of 51.6 ± 15.9 years. The peak Scr was 669.9 ± 299.8 μmol/L, and 95.7% of patients had stage 3 acute kidney injury (AKI). Drug-induced tubulointerstitial nephritis (TIN) was the most common cause (65.2%) of AKD, followed by severe nephrotic syndrome (17.4%). All patients had pathological changes indicating TIN, and 11 patients were complicated with the newly emerging glomerular disease (GD). The risk of oxalosis caused by increased enterogenous oxalate absorption accounted for only 26.1%, and others came from new kidney diseases. The majority (75%) of abundant (medium to severe) oxalosis occurred in patients without GD. There were no significant differences in the score for tubular injury (T-IS) and interstitial inflammation with different severities of oxalosis. Rate of Scr decrease (ΔScr%) at 2 weeks was negatively correlated with the severity of oxalosis (R = -0.542, p = 0.037), score for T-IS (R = -0.553, p = 0.033), and age (R = -0.736, p = 0.002). The decrease in Scr at 4 weeks was correlated with T-IS (R = -0.433), but had no correlation with oxalosis. CONCLUSIONS: The present findings revealed that 95.7% of AKD with secondary renal oxalosis occurred in critically ill patients. AKD from tubular injury was the prominent cause. Severe oxalosis contributed to delayed early recovery of AKD.
OBJECTS: This study aimed to analyze the clinicopathological features of acute kidney disease (AKD) with renal oxalosis. METHODS: Data for biopsy-proven AKD with oxalosis diagnosed from Jan 2011 to Oct 2018 was collected. The underlying diseases, dietary habits, clinical and pathological characteristics of newly emerging kidney disease were analyzed. The long-term renal prognosis was observed. RESULTS: A total of 23 patients were included, comprised of 18 men and 5 women with a mean age of 51.6 ± 15.9 years. The peak Scr was 669.9 ± 299.8 μmol/L, and 95.7% of patients had stage 3 acute kidney injury (AKI). Drug-induced tubulointerstitial nephritis (TIN) was the most common cause (65.2%) of AKD, followed by severe nephrotic syndrome (17.4%). All patients had pathological changes indicating TIN, and 11 patients were complicated with the newly emerging glomerular disease (GD). The risk of oxalosis caused by increased enterogenous oxalate absorption accounted for only 26.1%, and others came from new kidney diseases. The majority (75%) of abundant (medium to severe) oxalosis occurred in patients without GD. There were no significant differences in the score for tubular injury (T-IS) and interstitial inflammation with different severities of oxalosis. Rate of Scr decrease (ΔScr%) at 2 weeks was negatively correlated with the severity of oxalosis (R = -0.542, p = 0.037), score for T-IS (R = -0.553, p = 0.033), and age (R = -0.736, p = 0.002). The decrease in Scr at 4 weeks was correlated with T-IS (R = -0.433), but had no correlation with oxalosis. CONCLUSIONS: The present findings revealed that 95.7% of AKD with secondary renal oxalosis occurred in critically ill patients. AKD from tubular injury was the prominent cause. Severe oxalosis contributed to delayed early recovery of AKD.
Authors: Sushrut S Waikar; Anand Srivastava; Ragnar Palsson; Tariq Shafi; Chi-Yuan Hsu; Kumar Sharma; James P Lash; Jing Chen; Jiang He; John Lieske; Dawei Xie; Xiaoming Zhang; Harold I Feldman; Gary C Curhan Journal: JAMA Intern Med Date: 2019-04-01 Impact factor: 21.873
Authors: Lakhmir S Chawla; Rinaldo Bellomo; Azra Bihorac; Stuart L Goldstein; Edward D Siew; Sean M Bagshaw; David Bittleman; Dinna Cruz; Zoltan Endre; Robert L Fitzgerald; Lui Forni; Sandra L Kane-Gill; Eric Hoste; Jay Koyner; Kathleen D Liu; Etienne Macedo; Ravindra Mehta; Patrick Murray; Mitra Nadim; Marlies Ostermann; Paul M Palevsky; Neesh Pannu; Mitchell Rosner; Ron Wald; Alexander Zarbock; Claudio Ronco; John A Kellum Journal: Nat Rev Nephrol Date: 2017-02-27 Impact factor: 28.314
Authors: Majuran Perinpam; Felicity T Enders; Kristin C Mara; Lisa E Vaughan; Ramila A Mehta; Nickolay Voskoboev; Dawn S Milliner; John C Lieske Journal: Clin Biochem Date: 2017-07-29 Impact factor: 3.281